Agios Pharmaceuticals

ISIN US00847X1046

 | 

WKN A1W2RM

Market cap (in EUR)
1,352 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Quote

Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Chart

Financials

Key metrics

Market capitalisation, EUR 1,352 m
EPS, EUR -6.30
P/B ratio 1.2
P/E ratio 3.8
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 34 m
Net income, EUR 623 m
Profit margin 1,845.92%

What ETF is Agios Pharmaceuticals in?

There are 4 ETFs which contain Agios Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Agios Pharmaceuticals is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.21%
Equity
United States
Health Care
Biotech
44
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
485
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.00%
Equity
North America
Social/Environmental
27
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.04%
Equity
United States
Small Cap
177

Performance

Returns overview

YTD +1.30%
1 month -1.68%
3 months -31.98%
6 months -23.03%
1 year -25.24%
3 years -14.60%
5 years -35.18%
Since inception (MAX) -47.60%
2025 -27.36%
2024 +53.62%
2023 -19.14%
2022 -13.92%

Monthly returns in a heat map

Risk

Risk metrics in this section:
 
  • Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
  • Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
  • Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
ETF returns include dividend payments (if applicable).
Show more Show less

Risk overview

Volatility 1 year 66.71%
Volatility 3 years 56.01%
Volatility 5 years 54.24%
Return per risk 1 year -0.38
Return per risk 3 years -0.09
Return per risk 5 years -0.15
Maximum drawdown 1 year -49.49%
Maximum drawdown 3 years -66.01%
Maximum drawdown 5 years -68.48%
Maximum drawdown since inception -68.48%

Rolling 1 year volatility

— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.